PLASMA CELL MYELOMA REFRACTORY
Clinical trials for PLASMA CELL MYELOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new PLASMA CELL MYELOMA REFRACTORY trials appear
Sign up with your email to follow new studies for PLASMA CELL MYELOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for myeloma patients who have run out of options
Disease control Recruiting nowThis study is testing several new drug combinations for people with multiple myeloma that has returned or stopped responding to standard treatments. The main goal is to find safe and effective doses and see if these new combinations can shrink the cancer. Participants will be adu…
Matched conditions: PLASMA CELL MYELOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope for multiple myeloma patients Who've run out of options
Disease control Recruiting nowThis is the first human study of an experimental antibody drug called SAR446523 for people with multiple myeloma that has returned or stopped responding to other treatments. The trial aims to find the safest and most effective dose by testing different amounts in about 87 partici…
Matched conditions: PLASMA CELL MYELOMA REFRACTORY
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for Tough-to-Treat blood cancer: experimental combo therapy enters testing
Disease control Recruiting nowThis study is testing a new way to give a combination of three drugs to adults whose multiple myeloma has returned or stopped responding to previous treatments. The main goal is to see how well the treatment works to shrink the cancer. Researchers are also looking at side effects…
Matched conditions: PLASMA CELL MYELOMA REFRACTORY
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC